Analytical Data
-
Gene name
KLRG2
- Application
-
Alternative Names
C-type lectin domain family 15 member B
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A4D1S0
-
Expression Region
1-409aa
-
Molecular Weight
44.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KLRG2, or Killer Cell Lectin Like Receptor G2, is a crucial member of the C-type lectin-like receptor family predominantly expressed on natural killer (NK) cells and certain T lymphocyte subsets. Its role in immune regulation has garnered significant attention in recent years, as KLRG2 is involved in the inhibition of effector functions and the modulation of cell survival, linking it to immune tolerance and exhaustion in chronic infections and cancer. Research indicates that KLRG2 negatively regulates the activation of NK cells and T cells, which suggests its potential as a therapeutic target for enhancing anti-tumor immunity or reinvigorating exhausted immune cells. Additionally, understanding the structural and functional characteristics of KLRG2, particularly through the development of recombinant proteins, provides valuable insights into its ligand interactions and downstream signaling pathways. These studies aim to delineate the receptor's mechanisms in immune responses and explore its application in immunotherapy strategies. As a result, the recombinant KLRG2 protein serves as a valuable tool for investigating its role in immunological contexts and for exploring new avenues in treatment modalities for various diseases, including malignancies and chronic viral infections. The exploration of KLRG2's functions and interactions represents a promising frontier in immunology, potentially leading to novel therapeutic approaches leveraging this receptor for better immune system modulation.
